Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is often linked to stress. Although short-term stress is without effect in mice, prolonged stress leads to depressive-like behavior, indicating that an allostatic mechanism exists in this difference. Here we demonstrate that mice after short-term (1 h per day for 7 days) chronic restraint stress (CRS), do not display depressive-like behavior. Analysis of the hippocampus of these mice showed increased levels of neurotrophic factor-α1 (NF-α1; also known as carboxypeptidase E, CPE), concomitant with enhanced fibroblast growth factor 2 (FGF2) expression, and an increase in neurogenesis in the dentate gyrus. In contrast, after prolonged (6 h per day for 21 days) CRS, mice show decreased hippocampal NF-α1 and FGF2 levels and depressive-like responses. In NF-α1-knockout mice, hippocampal FGF2 levels and neurogenesis are reduced. These mice exhibit depressive-like behavior that is reversed by FGF2 administration. Indeed, studies in cultured hippocampal neurons reveal that NF-α1 treatment directly upregulates FGF2 expression through extracellular signal-regulated kinase-Sp1 signaling. Thus, during short-term CRS, hippocampal NF-α1 expression is upregulated and has a key role in preventing the onset of depressive-like behavior through enhanced FGF2-mediated neurogenesis. To evaluate the therapeutic potential of this pathway, we examined, rosiglitazone (Rosi), a PPARγ agonist, which has been shown to have antidepressant activity in rodents and humans. Rosi upregulates FGF2 expression in a NF-α1-dependent manner in hippocampal neurons. Mice fed Rosi show increased hippocampal NF-α1 levels and neurogenesis compared with controls, thereby indicating the antidepressant action of this drug. Development of drugs that activate the NF-α1/FGF2/neurogenesis pathway can offer a new approach to depression therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“A oneway ANOVA reported a significant effect of treatment [F(5, 12)=63.”
Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Adult hippocampal neurogenesis buffers stress responses and depressive behaviour
Snyder, J. S., Soumier, A., Brewer, M., Pickel, J., & Cameron, H. A. (2011) · Nature · doi:10.1038/nature10287 · Cited by 1,473
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Kempton, M. J., Salvador, Z., Munafò, M. R., Geddes, J. R., Simmons, A., Frangou, S., & Williams, S. C. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.60 · Cited by 886
Hippocampal damage associated with prolonged and fatal stress in primates
Uno, H., Tarara, R., Else, J., Suleman, M., & Sapolsky, R. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-05-01705.1989 · Cited by 728
Antidepressants increase neural progenitor cells in the human hippocampus
Boldrini, M., Underwood, M. D., Hen, R., Rosoklija, G. B., Dwork, A. J., John Mann, J., & Arango, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.75 · Cited by 686
Neural stem cell proliferation is decreased in schizophrenia, but not in depression
Reif, A., Fritzen, S., Finger, M., Strobel, A., Lauer, M., Schmitt, A., & Lesch, K.-P. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001791 · Cited by 630
Cited by
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
Wei, Z.-X., Xie, G.-J., Mao, X., Zou, X.-P., Liao, Y.-J., Liu, Q.-S., Wang, H., & Cheng, Y. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0622-2 · Cited by 227
“Immunohistochemistry To analyze adult hippocampal neurogenesis and/or newborn mature neurons after different treatments in the mice, we immunostained doublecortin (DCX), 5-BrdU and NeuN in the dentate gyrus of hippocampus by immunohistochemistry as described previously [17].”
MethodInsulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes
Lyra e Silva, N. D. M., Lam, M. P., Soares, C. N., Munoz, D. P., Milev, R., & De Felice, F. G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00057 · Cited by 164
Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders
Galvez-Contreras, A. Y., Campos-Ordonez, T., Lopez-Virgen, V., Gomez-Plascencia, J., Ramos-Zuniga, R., & Gonzalez-Perez, O. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.004 · Cited by 112
Brooker, S. M., Gobeske, K. T., Chen, J., Peng, C.-Y., & Kessler, J. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.160 · Cited by 61
Dattilo, V., Amato, R., Perrotti, N., & Gennarelli, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00826 · Cited by 49
Depression, antidepressants, and insulin resistance: which link?
Fanelli, G., & Serretti, A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.011 · Cited by 39
Metadata
- Authors
- Cheng, Y., Rodriguiz, R. M., Murthy, S. R. K., Senatorov, V, Thouennon, E., Cawley, N. X., Aryal, D. K., Ahn, S., Lecka-Czernik, B., Wetsel, W. C., & Loh, Y. P.
- Venue
- Molecular Psychiatry
- Published
- 2014-10-21
- Volume
- 20
- Issue
- 6
- Pages
- 744-754
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2020074950
- Cited by
- 77
- References
- 17
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.